- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03833882
Evaluation of MAF-1217 in Patients With DED
Evaluation of the Performance of the Tear Substitute MAF-1217 in Patients With Evaporative DED
This is a pre-market, multicentre, double-blind, randomized, crossover, non-inferiority study comparing the efficacy of MAF-1217 and Cationorm® in adult patients with evaporative DED.
The study population will be divided in 4 different subgroups, according to the different types of evaporative DED:
- Group A: high evaporative levels
- Group B: females in menopause, whether using hormonal integration or not
- Group C: presence of active obstructive Meibomian gland disease
- Group D: glaucomatous patients
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Patients will be enrolled after having signed the informed consent form prior any other study procedure and after inclusion/exclusion criteria check.
Each patient will be planned to perform 6 study visits and at each visit all necessary study procedures will be performed according to the clinical investigation plan requirements (see flow-chart).
The study visits will be performed at: screening, baseline, week 2, week 6, week 8, week 12.
Patients will be enrolled at screening visit and at baseline, after the wash-out period of 1 week, then will be randomized to receive MAF-1217 or Cationorm® for the following 6 weeks.
After this time lapse, patients will be switched to the opposite therapy for 6 additional weeks.
The entire study population will be asked for a TID posology, and will be divided in 4 different subgroups, according to the different types of evaporative DED.
Certain test will be performed only in some patients:
Osmolimetry and tear sampling in 20 patients(10/site) chosen random from groups B, C and D; Ferning test only in group D; tear film collection and cytokine expression only in 20 patients form site nr. 2.
Patients will be allowed to carry on any systemic or local medications, apart lubricating eyedrops, which have to be stopped the day before baseline visit.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Milan, Italië, 20121
- Ospedale San Paolo, ASST Santi Paolo e Carlo
-
Milan, Italië, 20157
- ASST Fatebenefratelli Sacco P.O.L. Sacco
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- At least 18 years old (adult patients), male and female
- Schirmer I test > 10 mm at 5'
- (Group A): high evaporative levels
- (Group B): females in menopause, both using hormonal integration or not
(Group C): presence of active obstructive Meibomian gland disease, defined as at least one of the following:
- Meibomian orifice plugging
- eyelid margin foaminess
- changes in orifice position with respect to the mucocutaneous junction
- abnormal Meibomian gland secretions (opaque and viscous-like form that is difficult to express)
- (Group D): glaucomatous patients receiving one or more BAK preserved treatments for at least 2 years, showing an abnormal Ferning test (Types 3 or 4 according to Rolando)
- all: wishing to participate in the study and able to sign the ICF
Inclusion criteria to be checked at baseline:
- BUT < 7"
- Mild to severe DED according to OSDI chart
Exclusion Criteria:
- Neuropathic causes of dry eye (diabetes, long-standing contact lens wearing, previous ocular herpes infections)
- Coexisting corneal diseases
- Autoimmune diseases
- Past or active cicatricial conjunctivitis
- Past ocular surface burns
- Keratinization of the eyelid margin
- Sjogren syndrome
- History of corneal trauma
- Pregnant and lactating women
- Younger than 18 years old patients
- Use of contact lenses
- inability to self administer study medications
- (GROUPS B, D) Presence of active obstructive Meibomian gland disease
- (GROUP C) Presence of cicatricial Meibomian gland disease
- known allergic sensitivity to any of the devices ingredients or any other known allergy
- participation in a clinical trial during the 3 months prior to the beginning of the study
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: MAF1217/Cationorm
|
The study population will have to self-administer the study treatment in a TID posology.
The study population will have to self-administer the study treatment in a TID posology.
|
|
Experimenteel: Cationorm/MAF1217
|
The study population will have to self-administer the study treatment in a TID posology.
The study population will have to self-administer the study treatment in a TID posology.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Break-up time (BUT) differences
Tijdsspanne: measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
Changes in break-up time (BUT) versus baseline
|
measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
ocular surface staining (corneal and conjunctival)
Tijdsspanne: measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
Cross-over analysis for the differences versus baseline between the two groups on changes in ocular surface staining (corneal and conjunctival)
|
measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
|
Schirmer I test (ST) (without anesthesia)
Tijdsspanne: measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
Cross-over analysis for the differences versus baseline between the two groups on changes in Schirmer I test (ST) (without anesthesia)
|
measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
|
number of blinking per minute
Tijdsspanne: measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
Cross-over analysis for the differences versus baseline between the two groups on changes in number of blinking per minute
|
measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
|
Ferning test (Group D)
Tijdsspanne: measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
Cross-over analysis for the differences versus baseline between the two groups on changes in Ferning test (Group D)
|
measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
|
osmolarity
Tijdsspanne: measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
Cross-over analysis for the differences versus baseline between the two groups on changes in osmolarity
|
measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
|
patient satisfaction (10 points VAS scale)
Tijdsspanne: measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
Cross-over analysis for the differences versus baseline between the two groups on changes in patient satisfaction (10 points VAS scale). (VAS: scale where patient has to specify level of satisfaction by indicating a position along a continuous line between two end-points (0 - 10). 0 indicates no satisfaction while 10 represents the highest level). |
measured at week 2, 6, 8 and 12 weeks treatment versus baseline
|
|
OSDI
Tijdsspanne: measured at week 2, 6, 8 and 12 weeks treatment
|
Changes in questionnaire scores (OSDI - Ocular Surface Disease Index).
The overall Ocular Surface Disease score defined the ocular surface as normal (0-12 points) or as having mild (13-22 points), moderate (23-32 points), or severe (33-100 points) disease.
|
measured at week 2, 6, 8 and 12 weeks treatment
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- VF-OS-001/2018
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .